EMPEROR_HFrEF

A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with reduced Ejection Fraction (HFrEF).

Stage: klaar
Medicine: empagliflozin
Population: Hartfalen
Phase: III
First Patient In: 25 July 2017
Last Patient In: 9 September 2019
Last Patient Last Visit: -

Study Director

dr. R.G.E.J. Groutars

Cardioloog